Amid Covid-19 hunt, Pfizer adds Lyme disease vaccine in $308M deal with Valneva

In the midst of their $500 million program to build a Covid-19 vaccine with BioNTech, Pfizer has announced a sizable deal to commercialize a vaccine for a far different disease.